Aim immunotech inc. (HEB)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-9,533

-9,827

-8,259

-7,502

-15,230

-17,450

-16,225

-

-

-

-

Adjustments to reconcile net loss to net cash used in operating activities:
Net loss

-

-

-

-

-

-

-

-17,354

-9,015

-13,136

-7,180

Depreciation of property and equipment

735

856

948

1,119

941

665

671

643

465

407

359

Amortization and abandonment of patent and trademark rights

-

-

63

184

249

477

196

-

-

-

-

Amortization and abandonment of patent and trademark rights

-

-

-

-

-

-

-

40

165

373

381

Redeemable warrants valuation adjustment

-1,510

-1,165

-2,417

-1,677

0

-14

-281

-

-

-

-

Fair value of convertible note adjustment

-70

582

-

-

-

-

-

-

-

-

-

Extinguishment of convertible note

345

-

-

-

-

-

-

-

-

-

-

Amortization of patent, trademark rights

57

22

-

-

-

-

-

-

-

-

-

Changes in ROU assets

37

-

-

-

-

-

-

-

-

-

-

Equity-based compensation

853

929

571

-

-

-

-

-

-

-

-

Capitalized construction interest

-

-

-

-

-

-

143

85

0

-

-

Issuance of common stock for accounts payable

-

-

-

-

-

-

-

384

71

329

1,382

Equipment acquired by capital leases

-

-

-

-

-

-

-

-

62

200

0

Unrealized loss on marketable securities

-

-

-

-

-

-

-

346

-585

-974

-

Unrealized losses on investments

-

-

-

-

-

-

-

-

-

-

0

Redeemable warrants valuation adjustment

-

-

-

-

-

-

-

-85

-2,425

-879

-6,258

Finance costs amortization and for Standby Financing

-

-

-

-

-

-

-

-

-

-

-241

Redeemable warrants valuation adjustment

-

-

-

-

-

-

-

-

-

879

6,258

Equity-based compensation

-

-

-

410

181

326

376

356

377

741

-826

Other-than-temporary impairment of marketable securities

-

-

-

0

315

145

800

-

-

-

-

Realized (gain) loss on sale of marketable securities

-

-

17

-57

-63

46

-

-

-

-

-

Gain on sale of building

-

223

-

-

-

-

-

-

-

-

-

Amortization of finance and debt issuance costs

288

263

37

0

0

-

-

-

-

-

-

Unrealized gain on securities

-

-

-

-

-

-

71

-

-

-

-

Other-than-temporary impairment of marketable securities

-

-

-

-

-

-

-

9

69

-

0

Inventory reserve

-

-

-

-

-

-

453

1,023

0

-

-

Change in assets and liabilities:
Accounts and other receivables

-274

1,070

-

-

-

-

-

-

-

-

-

Gain on disposal of equipment

-

-

-

-

-

-

-

-

-

-

83

Inventories

-

-

-

0

1,326

0

0

579

110

-77

0

Prepaid expenses and other current assets

-29

251

13

-26

-64

41

36

-

-

-

-

Lease liability

37

-

-

-

-

-

-

-

-

-

-

Accounts receivable

-

-

24

0

0

-

-

-

-

-

-

Prepaid expenses and other assets

-

-

-

-

-

-

-

-200

247

-46

-93

Other assets

-

-

-

-

-

-

-

-

-

-

5

Accounts payable

-207

166

566

-326

-196

-869

-617

860

424

362

1,884

Accrued interest expense

129

-

-

-

-

-

-

-

-

-

-

Accrued expenses

-731

-922

604

329

-1,114

1,105

-2,167

1,751

201

123

445

Net cash used in operating activities

-9,067

-10,640

-7,941

-7,380

-16,053

-13,964

-

-13,136

-10,096

-11,886

-9,297

Cash flows from investing activities:
Proceeds from sale of marketable securities

-

831

-

-

-

-

-

-

-

-

-

Office rental deposit

-

-

-

-

-

-

71

-

-

-

-

Deposits on capital leases refunded

-

-

-

-

-

-

0

-

-

-

-

Office rental deposit

-

-

-

-

-

-

-

0

0

-

-

Deposits on capital leases refunded

-

-

-

-

-

-

-

-6

4

9

0

Proceeds from sale of marketable securities

-

-

2,799

3,370

6,842

3,294

-

22,658

20,896

7,448

0

Purchase of marketable securities

5,782

-

-

-

-

-

-

32,765

10,201

49,889

0

Net cash used in operating activities

-

-

-

-

-

-

-16,901

-

-

-

-

Purchase of property and equipment

68

51

20

160

240

504

898

5,755

1,802

729

332

Proceeds from sale of building

-

1,050

-

-

-

-

-

-

-

-

-

Purchase of patent and trademark rights

297

76

49

294

250

258

242

211

234

337

242

Net cash provided by (used in) investing activities

-6,147

92

2,730

2,916

6,352

2,532

-

-16,067

8,655

-43,516

-574

Cash flows from financing activities:
Proceeds from lease financing obligation

-

4,080

-

-

-

-

-

-

-

-

-

Finance and debt issuance costs

-

439

102

0

0

-

-

-

-

-

-

Financing obligation payments

340

264

-

-

-

-

-

-

-

-

-

Proceeds from note payable, net of issuance costs

3,632

3,059

1,900

0

0

-

-

-

-

-

-

Payoff of mortgage note payable

-2,210

-1,957

-

-

-

-

-

-

-

-

-

Security deposits paid

-

114

-

-

-

-

-

-

-

-

-

Payments on capital leases

-

-

-

-

-

-

-

47

71

42

0

Proceeds from sale of stock, net of issuance costs

15,303

5,070

2,417

4,744

9,681

12,817

249

23,003

0

292

55,570

Deposits on capital leases refunded

-

-

-

14

0

2

-

-

-

-

-

Sales and maturities of short-term and long-term marketable securities

-

-

-

-

-

-

23,550

-

-

-

-

Purchase of short-term and long-term marketable securities

-

-

-

-

-

-

0

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

22,339

-

-

-

-

Payments on capital leases

-

-

-

1

21

34

45

-

-

-

-

Proceeds from (payments on) Margin Account Loan

-

-

-

-

-

-

-

5,356

1,695

-

0

Proceeds from exercise of stock warrants and options

-

-

-

-

-

-

-

-

-

-

6,254

Net cash provided by financing activities

16,385

9,435

4,215

4,757

9,660

12,785

-

28,312

1,624

250

61,824

Net increase in cash and cash equivalents

1,171

-1,113

-

-

-

-

-

-

-

-

-

Payments on Margin Account Loan

-

-

-

-

-

-

7,051

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-6,847

-

-

-

-

Net increase in cash and cash equivalents

-

-

-996

293

-41

1,353

-1,409

-891

183

-55,152

51,953

Supplemental disclosures of non-cash investing and financing cash flow information:
Issuance of common stock for accounts payable and accrued expenses

-

-

-

-

-

-

269

-

-

-

-

Unrealized loss on marketable securities

-

-

16

92

63

-46

-71

-

-

-

-

Cash paid for interest expense

-

-

-

-

-

-11

16

-

-

-

-

Stock issued to settle accounts payable

129

330

898

0

672

59

-

-

-

-

-

Conversion of note payable in shares

1,236

-

-

-

-

-

-

-

-

-

-

Conversion of series B preferred

4,534

-

-

-

-

-

-

-

-

-

-

Operating Lease - Right of Use Assets

188

-

-

-

-

-

-

-

-

-

-

Fair value of redeemable warrants granted

-

-

2,050

2,454

0

-

-

-

-

-

-

Cash paid for interest expense

-

-

-

-

-

-

-

24

41

11

0

Cash paid for interest expense

-

-

101

0

3

-

-

-

-

-

-